Meda 'looking for acquisitions' as Mylan looks on
This article was originally published in Scrip
Swedish firm Meda, which is being stalked by US generics company Mylan, is increasing its search for an acquisition target, rather than readying itself to be acquired. The firm has twice rejected bids from Mylan in recent weeks (scripintelligence.com, 29 April 2014; 4 April 2014)
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.